Whole Exome Sequencing : Key Industry Dynamics

whole exome sequencing market size is projected to reach US$ 1,457.8 million by 2031 from US$ 414.5 million in 2023. The market is expected to register a CAGR of 17.02% during 2023-2031. Incorporation of artificial intelligence and machine learning algorithms and diagnosing and treating cancer using whole exome sequencing are likely to remain key trends in the market.

Whole exome sequencing is the next-generation technique that is widely preferred as a substitute for whole genome sequencing due to its advantages. As the whole sequencing technique reduces the time and cost of analyzing genetics, it also offers a reduction of time spent in the trial and error for the drug formulation.

Download PDF at :-
https://www.theinsightpartners.com/sample/TIPRE00005519/?utm_source=OpenPR&utm_medium=10309

Market leaders and key company profiles :
Thermo Fisher Scientific Inc.
Illumina, Inc.
Centogene AG
F. Hoffmann-La Roche AG
Psomagen, Inc. (previously Macrogen Corp.)
Pacific Biosciences of California, Inc.
GENEWIZ, Inc.
Bio-Rad Laboratories, Inc.
Eurofins Scientific
Stratos Genomics

If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Sr. Vice President - Research
Phone: +1-646-491-9876

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.